Amgen Expands Thyroid Eye Disease Bet With New AMG 732 Rollover Study
Amgen Inc (AMGN) announced an update on their ongoing clinical study.
End of Quarter Sale - 50% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The new Amgen Inc. rollover study, officially titled “An Open-label, Rollover Study for Participants With Thyroid Eye Disease Previously Enrolled in Amgen-sponsored AMG 732 Studies and Are Primary Proptosis Non-responders or Who Relapsed During the Safety Follow-up,” aims to test AMG 732 in tougher thyroid eye disease cases. It focuses on patients who did not respond or later relapsed, making the data highly relevant for real-world use.
AMG 732 is an injectable drug given under the skin and designed to treat thyroid eye disease, a condition that affects vision and appearance. In this trial, all participants receive AMG 732, so the update will offer a clear view of how well the drug works and how safe it is in this harder-to-treat group.
The study is interventional and Phase 2, with a single group design and no randomization, meaning every patient gets the same treatment. There is no masking, so both doctors and patients know they are getting AMG 732, and the main goal is treatment, not prevention or diagnosis, which simplifies how investors should read future outcomes.
The study was first submitted on 23 Feb 2026 and is currently listed as “Not yet recruiting,” signaling that patient enrollment has not started but regulatory and operational work is underway. The latest update on 2 Apr 2026 suggests Amgen is actively maintaining the record, a useful signal that planning for the program is progressing even before first dosing.
For investors, the key takeaway is that Amgen is doubling down on thyroid eye disease by targeting nonresponders and relapsed patients, a segment with high unmet need and strong pricing power. Positive data could support a broader label, strengthen Amgen’s position versus players in the thyroid eye space, and improve sentiment on the company’s mid-term growth story.
This ongoing study remains in setup with recent updates posted, and further details are available on the ClinicalTrials portal.
To learn more about AMGN’s potential, visit the Amgen Inc drug pipeline page.
